La Razón has published an article about a study addressing the involvement of fibroblasts in colon cancer being carried out by "La Caixa" and the Colorectal Cancer Lab, headed by Eduard Batlle, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) and a CIBERONC member.
Colon cancer is one of the most frequent types of cancer, and although treatment cures this disease for most patients, a large percentage develop metastases in vital organs. In this regard, immunotherapy is not effective for this kind of cancer, benefiting only 5% of patients. This is because the colon cancer cells develop a mechanism through which to evade the immune system. “Understanding the communication between cancer cells and fibroblasts, on the one hand, and between fibroblasts and the immune system, on the other, would allow us to identify those patients at risk of developing metastasis and to work with efficient therapies,” says Batlle.
Link to: La Razón
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).